JP2022523712A5 - - Google Patents

Info

Publication number
JP2022523712A5
JP2022523712A5 JP2021544181A JP2021544181A JP2022523712A5 JP 2022523712 A5 JP2022523712 A5 JP 2022523712A5 JP 2021544181 A JP2021544181 A JP 2021544181A JP 2021544181 A JP2021544181 A JP 2021544181A JP 2022523712 A5 JP2022523712 A5 JP 2022523712A5
Authority
JP
Japan
Application number
JP2021544181A
Other languages
Japanese (ja)
Other versions
JP2022523712A (ja
JPWO2020159824A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/015002 external-priority patent/WO2020159824A1/en
Publication of JP2022523712A publication Critical patent/JP2022523712A/ja
Publication of JP2022523712A5 publication Critical patent/JP2022523712A5/ja
Publication of JPWO2020159824A5 publication Critical patent/JPWO2020159824A5/ja
Pending legal-status Critical Current

Links

JP2021544181A 2019-01-29 2020-01-24 治療用化合物および組成物 Pending JP2022523712A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962798012P 2019-01-29 2019-01-29
US62/798,012 2019-01-29
PCT/US2020/015002 WO2020159824A1 (en) 2019-01-29 2020-01-24 Therapeutic compounds and compositions

Publications (3)

Publication Number Publication Date
JP2022523712A JP2022523712A (ja) 2022-04-26
JP2022523712A5 true JP2022523712A5 (https=) 2023-01-20
JPWO2020159824A5 JPWO2020159824A5 (https=) 2023-01-20

Family

ID=71841895

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021544181A Pending JP2022523712A (ja) 2019-01-29 2020-01-24 治療用化合物および組成物

Country Status (10)

Country Link
US (2) US20210361634A1 (https=)
EP (1) EP3917910A4 (https=)
JP (1) JP2022523712A (https=)
KR (1) KR20210119432A (https=)
CN (1) CN113784951A (https=)
AU (1) AU2020216887A1 (https=)
BR (1) BR112021014956A2 (https=)
CA (1) CA3128018A1 (https=)
IL (1) IL285167A (https=)
WO (1) WO2020159824A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2733405C2 (ru) 2014-02-07 2020-10-01 Экзитера Фармасьютикалз Инк. Терапевтические соединения и композиции
EP3749662A4 (en) 2018-02-07 2021-07-14 Exithera Pharmaceuticals Inc. THERAPEUTIC COMPOUNDS AND COMPOSITIONS
KR20210084581A (ko) * 2018-10-30 2021-07-07 엑시테라 파마슈티컬스 인코퍼레이티드 치료 화합물 및 조성물
TW202345825A (zh) * 2022-03-30 2023-12-01 大陸商四川海思科製藥有限公司 環狀內醯胺類化合物的注射用藥物組合物及其製備方法
CN117723658A (zh) * 2023-12-08 2024-03-19 山东齐都药业有限公司 Hplc法测定丁苯酞氯化钠注射液中羟丙基倍他环糊精的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003321364A (ja) * 2002-05-07 2003-11-11 Eisai Co Ltd シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
US20060128654A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
CA2648522A1 (en) * 2005-04-04 2006-10-12 Daiamed, Inc. Substituted azetidinones
CN103415301A (zh) * 2011-03-09 2013-11-27 德国杰特贝林生物制品有限公司 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂
RU2733405C2 (ru) * 2014-02-07 2020-10-01 Экзитера Фармасьютикалз Инк. Терапевтические соединения и композиции
US20190315711A1 (en) * 2016-12-23 2019-10-17 Exithera Pharmaceuticals, Inc. Therapeutic compounds and compositions

Similar Documents

Publication Publication Date Title
BR112023012656A2 (https=)
JP2022523712A5 (https=)
CN305623251S (https=)
CN305621710S (https=)
CN305535677S (https=)
CN305535305S (https=)
CN305534379S (https=)
CN305533789S (https=)
CN305532812S (https=)
CN305531962S (https=)
CN305529931S (https=)
CN305529502S (https=)
CN305529029S (https=)
CN305528818S (https=)
CN305528067S (https=)
CN305528006S (https=)
CN305526778S (https=)
CN306811245S (https=)
CN306718096S (https=)
CN306552196S (https=)
CN306247201S (https=)
CN306218845S (https=)
CN305875516S (https=)
CN305622203S (https=)
CN305619479S (https=)